Study guide
19.2 Dissolution & Excipients
DHA Pharmacist Licensing Assessment PHO5481
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Licensing Pathway
1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan
2 Cardiovascular Pharmacology
2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents
3 Endocrine & Metabolic Pharmacology
3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents
4 Anti-Infective Pharmacology
4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars
5 CNS, Psychiatric & Pain Pharmacology
5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine
6 Respiratory, GI & Hematology Pharmacology
6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents
7 Pharmaceutical Care: Cardiometabolic Disease
7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management
8 Pharmaceutical Care: Respiratory, Rheumatology & Infection
8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship
9 Counseling, Monitoring & Special Populations
9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making
10 Pharmaceutical Calculations I
10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation
11 Pharmaceutical Calculations II
11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents
12 UAE Pharmacy Law & Regulation
12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity
13 Controlled Drugs, Ethics & Pharmacovigilance
13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal
14 Pharmacokinetics I: ADME
14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination
15 Pharmacokinetics II: Kinetics, Dosing & TDM
15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring
16 OTC Medicines & Self-Care
16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin
17 Medication Safety
17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition
18 Sterile & Nonsterile Compounding
18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding
19 Pharmaceutics, Biopharmaceutics & Toxicology
19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes
20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics
20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics
19.2 Dissolution & Excipients
Key Takeaways Explain This Topic AI
The Noyes-Whitney equation dC/dt = (D·S/h)·(Cs − C) shows that dissolution rate rises with larger particle surface area (S), higher saturation solubility (Cs), greater diffusion coefficient (D), and thinner diffusion layer (h); under sink conditions C is negligible so the driving force approximates Cs.
Dissolution rate can be increased by micronisation (e.g. griseofulvin), salt formation, amorphous forms, and increased agitation; each lever maps to a specific term in the Noyes-Whitney equation.
Common tablet excipients include fillers/diluents (lactose, microcrystalline cellulose), binders (povidone, starch paste), disintegrants (croscarmellose, sodium starch glycolate, crospovidone), lubricants (magnesium stearate), glidants (colloidal silicon dioxide), preservatives (parabens, benzyl alcohol), and antioxidants (ascorbic acid, sodium metabisulfite).
Excessive magnesium stearate (a hydrophobic lubricant) slows disintegration and dissolution by forming a water-repellent film around particles — a classic exam trap linking excipient choice to bioavailability.
Dissolution testing uses USP Apparatus I (basket) and II (paddle); for BCS Class I and III drugs (highly soluble), dissolution profiles serve as a bioequivalence surrogate supporting biowaivers.
Last updated: August 2026
The Noyes-Whitney Equation
When a solid drug particle is placed in an aqueous medium, it dissolves through a diffusion layer at the particle surface. The Noyes-Whitney equation quantifies the dissolution rate:
dC/dt = (D · S / h) · (Cs − C)
- Symbol Meaning How to increase it
- D Diffusion coefficient of the drug in the medium Higher temperature, lower viscosity
- S Surface area of the solid exposed to the medium Smaller particles, micronisation
- h Thickness of the stagnant diffusion layer Increased agitation/stirring
- Cs Saturation solubility of the drug at the particle surface Salt forms, amorphous forms, pH adjustment
- C Bulk concentration of drug in the surrounding fluid Maintained low by sink conditions
The driving force for dissolution is the concentration gradient (Cs − C) . Under sink conditions , C is kept negligible (typically C < 0.1·Cs), so the gradient approximates Cs and the equation simplifies to dC/dt ≈ (D·S/h)·Cs. Dissolution testing apparatus maintain sink conditions by using a large volume of medium.
Levers to increase dissolution — and the drug each illustrates
Strategy Noyes-Whitney term changed Classic example
Micronisation (particle size reduction) ↑ S (surface area) Griseofulvin — micronised griseofulvin has markedly higher bioavailability than the non-micronised form
Salt formation (e.g. sodium or hydrochloride salt) ↑ Cs (solubility) Sodium diclofenac dissolves faster than the free acid
Amorphous form (no crystal lattice energy to overcome) ↑ Cs Amorphous solid dispersions used for some BCS Class II drugs
Increased agitation ↓ h (diffusion layer) Paddle/basket rotation in dissolution testing
Exam trap: Do not confuse solubility (Cs, an equilibrium property of the molecule) with dissolution rate (dC/dt, a kinetic property of the formulation). A salt form raises Cs; micronisation raises S. Both increase dC/dt but through different terms in the equation.
Excipients: Functions and Clinical Pitfalls
Excipients are the inactive ingredients formulated alongside the active drug to produce a stable, manufacturable, and patient-acceptable dosage form. Although described as 'inert', excipients can influence dissolution, bioavailability, and tolerability.
Functional class Examples Function
Fillers / diluents Lactose , microcrystalline cellulose (MCC) Add bulk so the tablet is large enough to compress
Binders Povidone (PVP) , starch paste Hold granules together after compression
Disintegrants Croscarmellose sodium , sodium starch glycolate , crospovidone Swell on contact with water, causing the tablet to break apart
- Lubricants Magnesium stearate , stearic acid Reduce friction between granule and die wall during compression
- Glidants Colloidal silicon dioxide Improve powder flow into the die
Preservatives Parabens (methyl/propyl hydroxybenzoate), benzyl alcohol Prevent microbial growth in multi-dose liquids
Antioxidants Ascorbic acid , sodium metabisulfite Prevent oxidative degradation of the drug
Sweeteners, flavours, colours Sucrose, aspartame; vanillin; titanium dioxide, FD&C colours Improve palatability and aid identification
How excipients affect bioavailability and safety
Hydrophobic lubricants slow dissolution. Magnesium stearate is the classic culprit: at high concentrations or long blending times it coats drug particles with a water-repellent film, reducing wetting (effectively lowering S) and slowing disintegration. This is a favourite exam link between an excipient and reduced bioavailability. Using water-soluble lubricants (e.g. sodium stearyl fumarate) or limiting stearate concentration mitigates this.
Disintegrants are essential for rapid tablet breakdown. Without an effective disintegrant, disintegration (step 1 of oral absorption) is delayed and the entire absorption cascade slows.
Excipient allergies and intolerances. Lactose as a filler is problematic for lactose-intolerant patients; gelatin (capsule shells) is an animal-derived concern for some dietary and religious groups; gluten in starch-derived excipients matters in coeliac disease; parabens can cause contact dermatitis and rare hypersensitivity. A pharmacist must read the excipient list when a patient reports a reaction to a 'non-allergic' drug.
Dissolution Testing: Apparatus and Regulatory Role
Dissolution testing measures the amount of drug released from a dosage form into a defined medium over time, producing a dissolution profile that is both a quality control (QC) tool and a bioequivalence surrogate.
- USP Apparatus Name Typical use
- USP I Basket Capsules and dosage forms that tend to float
- USP II Paddle Immediate-release tablets (most common)
- USP III Reciprocating cylinder Extended-release products
- USP IV Flow-through cell Poorly soluble drugs, microparticles
For BCS Class I and III drugs (highly soluble), where rapid dissolution means absorption is not dissolution-limited, dissolution profile comparison (f2 similarity factor) can serve as a bioequivalence surrogate in lieu of an in-vivo pharmacokinetic study — the basis of the biowaiver . For Class II and IV drugs, in-vivo bioequivalence studies are generally still required because dissolution is rate-limiting and formulation-dependent.